FTO and cancer: A recent study showed that combination of FTO inhibitor and nilotinib can restrain the growth of leukemia and increase the sensitivity of leukemia cells to tyrosine kinase inhibitors, highlighting the potential therapeutic value of targeting m6A regulators in drug-resistant cancers.13